LDS/Medical Tests/Beta-Galactosidase, Fibroblasts

Beta-Galactosidase, Fibroblasts

Beta-Galactosidase is a lysosomal enzyme, composed of four identical polypeptides of 135,000 Daltons each. It is involved in the catabolism of sphingolipids and uses GM1 ganglioside and Keratan sulfate as substrates. Beta-Galactosidase deficiency is associated with three different autosomal recessive lysosomal storage disorders: GM1 gangliosidosis (GM1), Mucopolysaccharidoses, type IV-B (MPS IV-B) and galactosialidosis syndromes. GM1 and MPS-IV-B result from the mutations of GLB1 and galactosialidosis results from mutations in CTSA (cathepsin A) and produce decreased levels of beta galactosidase and neuraminidase.

Deficiency of beta-galactosidase enzyme leads to the accumulation of sphingolipids in neuronal tissues, which in turn cause central nervous system degradation (GM1), and also causes the accumulation of glycosaminoglycan keratan sulfate in bone cartilage, which causes skeletal deterioration effects (MPS-IV-B).

GM1 disorder progressively damages neurons of the brain and spinal cord. The occurrences of these diseases are 1 in 200,000 newborns. There are three forms of GM1, infant, juvenile, and adult, and all of them are the results of the same gene mutation. This condition is terminal and leads to premature death, with the exception of some adult cases.

Morquio syndrome is characterized by skeletal involvement and consists of two forms (MPS IV-A and MPS IV-B) with similar clinical findings. MPS IV-A results from the mutations in the gene encoding galactosamine-6-sulfate, and MPS IV-B are due to beta Galactosidase deficiency. This syndrome is a progressive disease and estimated to occur in 1 of every 200,000 births and typically starts at age 1-3 years.

Galactosialidosis is a rare autosomal recessive lysosomal storage disease, characterized by coarse facial features, macular cherry-red spots, vertebral deformities, epilepsy, action myoclonus, and ataxia. There are three different types: early infantile, late infantile and juvenile/adult galactosialidosis and are differentiated by the age at which symptoms develop and the pattern of features.

A careful review of the clinical history and presentation is necessary to differentiate between GM1 gangliosidosis, galactosialidosis and Morquio syndrome B as the beta-galactosidase levels are decreased in all three disorders. This test cannot reliably determine carrier status of MPS IV-B. Genetic testing is recommended. Molecular testing may also be used to confirm a diagnosis in many patients. However, two known or probable causative mutations may not be identified in all cases of Morquio’s syndrome.

  • Diagnosis of lysosomal storage disease associated with Mucopolysaccharidosis-IV-B (MPS-IV-B)
  • Diagnosis of Morquio B disease, and GM1 gangliosidosis (GM1) or galactosialidosis type syndromes
Decreased levels are consistent with Beta-Galactosidase deficiency (MPS 1V-B) (Morquio syndrome).

Greater or equal to 1.56 nmol/min/mg

Fluorometric enzyme assay using 4-Methylumbelliferone (MU) substrate.

Tissue culture cells. 

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7 days
Urinary Glycosaminoglycans (GAGs), Mucopolysaccharidosis Type IVB: GLB1 Gene Sequencing (BV), Mucopolysaccharoidosis Type IV-B: GLB1 Gene Deletion/Duplication (LY).

3-7 days.

Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login